Multimodal Computational Framework Can Predict Prognosis of Myelodysplastic Syndromes

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 26, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 26, 2025 -- A multimodal computational framework for patient stratification and prognosis prediction enables automatic identification of patient clusters, outperforming classical approaches for patients with myelodysplastic syndromes (MDS), according to a study published online in the April issue of Computer Methods and Programs in Biomedicine.

Cesare Rollo, from the University of Torino in Italy, and colleagues introduced a multimodal computational framework for patients' stratification and prognosis prediction (VAE-Surv). VAE-Surv integrates a variational autoencoder (VAE), which reduces the high-dimensional space that characterizes molecular data, with a deep survival model, combining embedded information with clinical features. The clinical robustness of the algorithm was tested by applying VAE-Surv to the Genomed4All cohort of MDS.

The researchers found that VAE-Surv achieved a median C-index of 0.78 when tested on 2,043 patients in the GenomMed4All cohort, outperforming classical approaches. Compared with a traditional approach that applies the clustering directly to the input data, the latent space enhanced the clustering performance. The analysis of the identified clusters showed that the proposed framework can capture existing clinical categorizations compared with the World Health Organization 2016 MDS subtypes while also suggesting novel, data-driven patient groups. VAE-Surv achieved a good prediction performance when tested in an external MDS cohort of 2,384 patients (median C-index, 0.74), preserving the interpretability of the main clinical and genetic features.

"VAE-Surv framework demonstrates the power of deep learning in handling the intricate genetic landscape of MDS, offering a novel, robust methodology for patient stratification and survival prediction," the authors write. "It stands to contribute significantly to personalized medicine in the context of hematologic disorders."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-27 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords